心不全 の ため の 心房 シャント
Alexander M Spring1, Andrea Scotti1, Julio Echarte-Morales1
1Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Structural heart : the journal of the Heart Team
|September 2, 2025
まとめ
標準的な治療法に反応しない進行性心不全 (HF) 患者のための新しい治療法です. このレビューは,HFスペクトル全体の心房シャントの生理学,装置,試験をカバーしています.
科学分野:
- 心臓病科
- 医療機器
- 心不全 の 治療
背景:
- 心不全 (HF) の薬理学的治療は,進行した段階の管理に制限があります.
- 進行したHFの症状の負担は,まだ満たされていない重要な臨床的需要です.
- 心房シャントはHF患者にとって新しい治療法として登場しました.
研究 の 目的:
- 心房シャントの分野を形作る 生理学,装置,臨床試験をレビューする
- HFの全スペクトルにわたる心房シャントの適用を調査する.
- 異なるタイプの心房間シャントとその潜在的な臨床的利点と限界を詳細に説明します.
主な方法:
- 心不全における心房シャントに関する既存の文献のレビュー.
- 心房シャント療法に基づく生理学的原理の分析
- 装置ベースの様々な非インプラントの心房間シャント戦略の検討.
主要な成果:
- 胸前シャントリングは 腹動性HFの治療法から HFのスペクトル全体に適用できる治療法へと進化しています
- 装置ベースの心房間シャント,インプラントなしのシャント,冠動脈シヌスシャントが調査されています.
- これらのシャントは,特定のHF患者集団に臨床的利益をもたらすことを目的としています.
結論:
- 症状のある進行性心不全の治療法として 有望な新薬です
- 患者の選択を最適化するために 生理学と器具の違いを理解することが重要です
- 各種の心房シャントの有効性と限界を完全に確立するには,さらなる試験が必要です.
さらに関連する動画
09:31Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
1.1K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.6K
関連する概念動画
01:20Mitral Regurgitation I: Introduction
55
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
55
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:22Mitral Stenosis I: Introduction
34
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
34
01:30Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37